cyrilzakka/clinical-trials huggingface dataset:
Teledermatology Versus Usual Care on Delay Before Diagnosis and Treatment of Dermatologic Conditions

In France, there is usually a long delay (approximately 6 weeks) before a general practitioner can obtain a specialized advice by dermatologists for diagnosis of "unusual" dermatologic conditions of their patients.

Previous studies have shown that teledermatology is a reliable way for diagnosis in dermatology.

We hypothesize that a teledermatology advice could reduce delay before diagnosis and therefore treatment for patients.

In France, there is usually a long delay (approximately 6 weeks) before a general practitioner can obtain a specialized advice by dermatologists for diagnosis of "unusual" dermatologic conditions of their patients.

Previous studies have shown that teledermatology is a reliable way for diagnosis in dermatology.

We hypothesize that a teledermatology advice could reduce delay before diagnosis and therefore treatment for patients.

Eligibility Criteria:
Inclusion Criteria:

* Consultation with a general practitioner for any motive during which, the general practitioner deems necessary to obtain a dermatologic expertise for a skin lesion (for diagnosis or treatment)

Exclusion Criteria:

* Emergency, assessed by the general practitioner (needs care or quick telephonic advice in the next 24 hours)
* Patients for which diagnosis and/or treatment are known by the general practitioner (the GP needs a dermatologic advice for a specific treatment (for example= laser, instrumental treatment...))
* Patient cannot go the dermatologic consultation by himself (for example: dependant patients...)
* Cognitive or psychiatric impairment (cannot give informed consent)
Quantitative Analysis of Outcomes in Breast Reconstruction

The first objective of this study is to assess the accuracy of digital image-processing techniques to provide measurements of human breast physical dimensions. The ultimate usefulness of these techniques is to develop quantitative outcome measures of the visual appearance of breast after local treatments for breast cancer. These measures will be used to improve clinical outcomes from multimodality therapy that includes surgery and radiotherapy and form the basis for the future development of patient decision making aids. The second objective is to evaluate the relationship between patient reported body image outcomes and measurement of human breast physical dimensions for patients with breast cancer.

If you agree to take part in this study, you will be asked to fill out a brief questionnaire packet. This packet contains questions about how you feel about your appearance and your overall well-being. You will be asked to have photographs of your breast(s) taken with two different types of digital cameras (2D and 3D). These are the same type of photographs routinely taken for all patients having breast reconstructive surgery. The photographs and measurements will be taken during your routine clinic visit. You will not be identifiable in the photographs.

The photographs will be used to develop automated methods for evaluating the appearance and shape of the breasts.

You may be asked to complete additional follow-up visits for this study. These visits would take place at a regularly-scheduled clinic visit that takes place just before a surgical procedure is planned. At these visits you would be asked to fill out another questionnaire packet and to allow the research the research staff to repeat the photographs. The number of follow-up visits needed would depend on your individual treatment plan. A final study visit would take place once you feel you are finished with your breast reconstructive process. At this point, your participation in the study would be completed. Breast reconstruction is different for each patient. The length of time of the reconstructive process depends on the procedure(s) that you and your surgeon have agreed upon. These options will be discussed at your regularly scheduled clinic appointments.

This is an investigational study. A total of up to 300 patients will take part in this study. All will be enrolled at UTMDACC.

Eligibility Criteria:
Inclusion Criteria:

1. Female
2. Age greater than 21 years old.
3. Candidate who has had or is planning to have breast reconstructive surgery and has at least one breast mound.
4. Willing to participate in the study and able to complete informed consent.
5. Proficient at reading and speaking English.

Exclusion Criteria:

1. Women who have undergone previous bilateral mastectomy without reconstruction.
2. Women who are unable to stand unassisted for 2 minutes.
3. Diagnosis of serious mental illness (e.g. schizophrenia) or cognitive impairment.
Personalized DC Vaccine for Postoperative Cancer

The study is aimed to the test efficacy and safety of neoantigen-primed dendritic cell (DC) cell vaccine therapy for postoperative locally advanced gastric cancer, hepatocellular carcinoma, lung cancer and colorectal cancer, and to explore the biomarkers related to efficacy and adverse event.

Postoperative patients with pathological confirmed locally advanced gastric cancer, hepatocellular carcinoma, non-small cell lung cancer and colorectal cancer with standard adjuvant treatment are enrolled. This is a prospective exploratory trial. Patients' tumor tissues are subsequent to whole exosome sequencing and possible neoantigens are identified. DC is in vitro primed with synthesized peptides. Both adverse events and responses are recorded.

Eligibility Criteria:
Inclusion Criteria:

* Participants with a first diagnosis of gastric cancer, hepatocellular carcinoma, non-small cell lung cancer, colorectal cancer who have undergone a curative resection or ablation
* Anticipated life time \> 3month
* Eastern Cooperative Oncology Group (ECOG) performance status (PS) 0 or 1
* Adequate organ functions

Exclusion Criteria:

* Any evidence of tumor metastasis or co-existing malignant disease
* Tumor emergency
* Abnormal coagulation condition
* Contagious diseases, such as hepatitis B virus, hepatitis C virus, human immunodefficiency virus, tuberculosis infection
* Concomitant tumors
* Immunological co-morbidities
Media Use in Preschooler Study (MUPS)

Childhood obesity is an epidemic and increasing. There are very few effective treatments for obesity in children. Recent studies have shown an association between obesity and sedentary behaviors such as television, video viewing and playing video games ('screen time') in preschool aged children. A school based intervention to reduce screen time in older children has been effective in preventing obesity.

The reduction of screen time may lead to the prevention of obesity and its complications in preschool children.

There have been no trials examining an intervention to decrease screen time in preschool children in the physician office setting. This setting is appealing for interventions directed to preschool children because of accessibility. In addition, other public health interventions implemented in a physician office setting, such as home safety advice, have been effective.

The proposed study design will be a randomized controlled trial. The intervention group will receive the study intervention, which is a 15 minute session about the health impact of screen time in children and strategies to decrease screen time.

The objective of this study is to determine if an office based intervention is effective in decreasing screen time (television, video viewing and playing video games) in preschool children.

Eligibility Criteria:
Inclusion Criteria:

* registered to attend a 3 year old well child visit

Exclusion Criteria:

* children with limitations in ambulation or cognitive delay will be excluded from the study.
Histocompatibility Leukocyte Antigen (HLA)-A*0201 Restricted Peptide Vaccine Therapy in Patients With Breast Cancer

The purpose of this study is to evaluate the safety and time to progression of HLA-A\*0201 restricted epitope peptides VEGFR1 and VEGFR2 emulsified with Montanide ISA 51 in advanced breast cancer patients.

VEGF receptor 1 and 2 are essential targets to tumor angiogenesis, and we identified that peptides derived from these receptors significantly induce the effective tumor specific CTL response in vitro and vivo. According to these findings, in this trial, we evaluate the safety, immunological and clinical response of those peptides. Patients will be vaccinated twice a week for 8 weeks. On each vaccination day, VEGFR1 peptide (1mg) and VEGFR2 peptide (1mg) mixed with Montanide ISA 51 will be administered by subcutaneous injection. Repeated cycles of the vaccine will be administered until patients develop progressive disease or unacceptable toxicity, whichever occurs first. In the phase I study, we evaluate the safety and tolerability of these peptide vaccine. In the following phase II study, we evaluate the immunological and clinical response of this vaccine therapy.

Eligibility Criteria:
Inclusion Criteria:

* Advanced or recurrent breast cancer
* Resistant against anthracycline-based and taxane-based chemotherapy or difficult to continue the chemotherapy due to intolerable side effect(s)
* Resistant against trastuzumab or difficult to continue it due to intolerable side effect(s) when her-2 is positive
* ECOG performance status 0-2
* Life expectancy \> 3 months
* HLA-A\*0201
* Laboratory values as follows

  * 2000/mm3\<WBC\<15000/mm3
  * Platelet count\>100000/mm3
  * Bilirubin \< 3.0mg/dl
  * Asparate transaminase \< 150IU/L
  * Alanine transaminase \< 150IU/L
  * Creatinine \< 3.0mg/dl
* Able and willing to give valid written informed consent

Exclusion Criteria:

* Pregnancy(woman of childbearing potential:Refusal or inability to use effective means of contraception)
* Breastfeeding
* Active or uncontrolled infection
* Unhealed external wound
* Concurrent treatment with steroids or immunosuppressing agent
* Prior chemotherapy,radiation therapy, or immunotherapy within 4 weeks
* Uncontrolled brain and/or intraspinal lesion(s)
* Decision of unsuitableness by principal investigator or physician-in-charge
An Evaluation of the Effectiveness of a Simple Marketing Intervention in Changing Student Attitudes to Depression

The purpose of this study is to determine the effectiveness of a simple marketing intervention in changing attitudes towards depression and its treatment among university students.

Depression is a major public health problem. It is common, affecting approximately 10 percent of the United Kingdom (UK) community at any one time. Britain's student population is particularly at risk.

Knowledge of effective treatments for depression is burgeoning thanks to a rapid increase in the quantity and quality of relevant research. Regardless of these advances, depression is still under-reported (Freeling et al., 1985) and general practitioners often fail to diagnose it.

When depression is correctly diagnosed, most patients in primary care will receive a prescription for an antidepressant. However, some patients will not have the prescription dispensed, and most will not complete the full recommended course. Compliance with psychological treatments is also a problem.

Study Design:

* Pilot work: The intervention consisted of mailing (to each undergraduate student's pigeon-hole) a pack of 4 postcards which provided brief information on depression in an attractive format. One postcard summarised information on depression as an illness; one summarised information on the causes of depression; one summarised information on the treatment of depression; and one summarised information on how to seek help for depression. Prior to the trial, the drafts were revised through feedback from a focus group of 5 students, who discussed the design and content of the draft postcards. The focus group participants were recruited from the Queen's College, as this college did not participate in the trial. The focus group contributed to the revision of the draft questionnaire.
* The trial: The design was a cluster, randomised, controlled trial. Individual Oxford University colleges which accept undergraduate students were the units of randomisation. Twenty-eight colleges were randomised. Permanent private halls and postgraduate colleges were excluded, as was the Queen's College (due to it being the lead investigator's college) and Harris Manchester College (a college for mature students).

Half of the randomised colleges received no intervention; the other half received the intervention.

A questionnaire was administered before and after the intervention to half of the undergraduate students in each of the colleges. The same questionnaire was used for both time points. Questions addressed knowledge of, and attitudes towards:

* depression as an illness;
* symptoms of depression;
* treatment for depression;
* sources of help for depression.

Eligibility Criteria:
Inclusion Criteria:

* Undergraduate students at Oxford University

Exclusion Criteria:

* Postgraduate students
* Students at the excluded colleges
A Pilot Trial to Determine the Efficacy of VSL#3 for Reducing Colonization by VRE

The purpose of this study is to investigate the feasibility, safety and efficacy of oral probiotic, VSL#3 versus oral placebo for reducing colonization by VRE.

Healthcare-associated infections are an important threat to patient safety. Currently, between 5 and 10 percent of patients admitted to acute care hospitals acquire one or more infections; healthcare-associated infections affect approximately 2 million patients each year in the United States, result in 90,000 deaths, and are associated with an added cost of $4.5 to $5.7 billion per year. Seventy percent of healthcare-associated infections are caused by antimicrobial resistant bacteria, such as vancomycin-resistant enterococcus (VRE), resulting in increased antimicrobial usage, morbidity and mortality, making prevention of multiresistant bacteria essential.

Eradication of colonization has been shown to greatly reduce infection; however, there are no reliable means of providing sustained eradication of colonization. No effective means of eradicating VRE intestinal colonization exist.

Probiotics containing strains of lactobacilli represent a novel approach to the prevention and control of antimicrobial resistance and have been studied extensively for a variety of infections. Even though various studies have shown probiotics to be effective for prevention of vaginal infections, urinary tract infections, etc no studies have examined the potential of probiotics to eradicate colonization by resistant pathogens, such as VRE.

Eligibility Criteria:
Inclusion Criteria:

* subjects will be male or female
* 18 years of age or older
* may or may not be hospitalized
* able to take oral medications
* have been found to be colonized with VRE or at high risk of being colonized by VRE and are not taking antibiotics

Exclusion Criteria:

* people on antibiotics will not be eligible to participate
Effect of Baduanjin on Functional Performance in Pre-Frail/Frail Older Adults

The aim for this study is to investigate the effectiveness of a 16-week realistic community-delivered Baduanjin training program compared to a waitlist control intervention, in improving functional outcomes among pre-frail and frail older adults in Singapore. It is hypothesized that participants that receive 16-week of BDJ training will have significant improvement in physical function (including balance, muscle strength, and endurance); alleviate exhaustion; reduce risk of falling and fear of falling; potentially reverse frailty; reduce depression; and improve quality of life, potentially with greater improvements in area(s) for individuals with lower baseline measures. Whereas, participants in the waitlist control group, will have insignificant changes to their baseline measures.


Eligibility Criteria:
Inclusion Criteria:

* Pre-frail and frail adults aged 55 years and above
* Able to ambulate (move about) without personal assistance and has no other physical limitations affecting participation and adherence
* Able to understand basic instructions
* Generally sedentary lifestyle

Exclusion Criteria:

* Participating in other intervention studies
* Perform regular moderate to vigorous intensity exercise
* Perform regular Taichi or Qigong exercise
* Have severe audio-visual impairment
* Diagnosed with cognitive impairment (e.g. dementia, Alzheimer's Disease) and/or history of neurological disorder (e.g. cerebral palsy, Parkinson's Disease)
* Diagnosed with postural hypotension (have a drop of 20mmHg systolic blood pressure, or a drop of 10mmHg diastolic blood pressure within two to five minutes of standing up, or if standing causes signs and symptoms)
* Unable to participate for the full duration of the study
* Unable to come to the training site by himself/herself or by the help of caregivers
* Not suitable to participate in exercise as deemed by a medical doctor
Endoscopic Mucosal Resection (EMR) in Barrett's Esophagus

Existing records will be reviewed to evaluate the predictors of complications including stricture formation, bleeding or perforation associated with endoscopic mucosal resection

Barrett's esophagus (BE) is a complication of gastroesophageal reflux disease in which the normal squamous lining of the esophagus is replaced by specialized columnar epithelium.1 Approximately 5%-10% of patients diagnosed with BE are thought to be at risk of developing esophageal adenocarcinoma.2 Patients with high-grade dysplasia (HGD) on biopsy are at the greatest cancer risk³. EMR is being performed clinically in our Barrett's Esophagus Unit on a regular basis during endoscopy for patients with Barrett's Esophagus and/or early esophageal adenocarcinoma. There are two predominant endoscopic mucosal resection (EMR) techniques exist using FDA approved devices - the EMR cap method using a transparent cap/snare combination and the endoscopic variceal ligation method using a band ligator/snare combination to resect tissue.

Eligibility Criteria:
Inclusion Criteria:

* Barrett's Esophagus Early Esophageal Adenocarcinoma History of Endoscopic Mucosal Resection

Exclusion Criteria:

* NA
Effect of Rosiglitazone on the Vascular Biology of Human Fat Tissue

Insulin resistance is a common condition that can lead to type 2 diabetes. One of the commonly prescribed diabetes medications, called rosiglitazone, works by decreasing insulin resistance. Rosiglitazone appears to work on fat cells. Animal studies suggest that rosiglitazone may work by increasing blood vessel growth in fat cells. The purpose of this research is to see if rosiglitazone also increases blood vessel growth in human fat cells. The investigators will compare results from before and after being on rosiglitazone for 6 weeks.

Adipocytes play a crucial role in the control of metabolic homeostasis, by sequestering excess calories in the form of triglycerides, and secreting cytokines that control systemic fuel utilization. Sustained excess calorie consumption results in adipocyte hypertrophy and hyperplasia, and like any expanding tissue, requires increased capillary expansion to nourish the enlarged adipose tissue mass. Recent reports indicate that decreased capillary density in adipose tissue of obese individuals correlates with insulin resistance, suggesting that an imbalance of angiogenesis and adipogenesis may underlie this condition. To determine whether improvement in insulin sensitivity is related to changes in adipose tissue capillary development, we conducted a randomized, double-blind, placebo-controlled trial to determine capillary density, angiogenic growth potential, and metabolic parameters in healthy human volunteers before and after treatment with rosiglitazone, a potent insulin sensitizer.

Eligibility Criteria:
Inclusion Criteria:

1. Overweight but otherwise in good general health.
2. Age 18 - 55 years.
3. Normal glucose tolerance.
4. Stable weight with BMI (27-44).
5. Stable medication use for the preceding month.
6. BP \< 150/90.
7. Negative pregnancy test (\*HCG), if female and of childbearing potential.
8. Practicing, and willing to continue to practice appropriate contraception throughout the study if a female of childbearing potential.

Exclusion Criteria:

1. Serious medical illness.
2. Pregnancy.
3. Tobacco use within the past 6 months.
4. Prior or current treatment with a thiazolidinedione.
5. Patients who have received an investigational drug in the past 30 days.
6. Use of systemic corticosteroids.
7. Known or suspected allergy to Rosiglitazone or any component of the preparation
SCOR in Neurobiology of Sleep--Intermediate Traits for Sleep Apnea

To determine intermediate traits for sleep apnea in a case-control study.

BACKGROUND:

Sleep apnea is a common condition that affects 4 percent of middle-aged males and 2 percent of middle-aged females. There is recent evidence that there is a genetic influence because first degree relatives of patients with this disorder have an increased risk of having obstructive sleep apnea. The basis for this increased familial risk is undefined. The investigators postulated that there were three specific intermediate traits, each of which reduced upper airway size, thereby increasing the risk of sleep apnea. These intermediate traits included: a) particular distribution of fat in the neck; b) craniofacial structure; and c) size of critical soft tissues in the airway (soft palate, tongue, lateral pharyngeal walls). All of these risk factors could be assessed quantitatively using advanced magnetic resonance imaging and novel volumetric image analysis techniques that had been developed..

The study was one project within a Specialized Center of Research in Neurobiology of Sleep and Sleep Apnea.

DESIGN NARRATIVE:

The case-control study identified the structural risk factors for sleep apnea. The study was complemented by studies in siblings of the patients and controls in order to identify those traits that demonstrated family aggregation not explained by shared environmental factors. The investigators believed that these structural risk factors would interact to increase the risk of sleep apnea. The elucidation of upper airway structural risk factors should provide the basis for developing new, more effective techniques for screening patients for sleep apnea and provide the basis for performing future DNA analyses aimed at identifying the genetic loci for these risk factors.

The specific aims were: 1) to quantify upper airway craniofacial structure, soft tissues and regional fat deposition using three dimensional magnetic resonance imaging in order to determine the intermediate traits associated with obstructive sleep apnea utilizing a case control design in normals and apneics; and 2) to determine the upper airway structural risk factors for sleep apnea that demonstrated family aggregation and were most likely to have a genetic component by comparing probands, siblings of probands, neighborhood controls and siblings of neighborhood controls. The resources included an extensive clinical sleep practice, sophisticated NM imaging techniques, novel volumetric computer graphics image analysis and expertise in molecular epidemiology, craniofacial structure, and the genetics of obesity.

Eligibility Criteria:
No eligibility criteria